



VASCERN Hereditary Haemorrhagic Telangiectasia (HHT) Working Group – Statement concerning SARS-CoV-2 vaccination for patients with HHT

General statement

Follow the national safety advice for social distancing, mask wearing etc.
Vaccination is important for the whole population but it remains your own choice.

Recommendation for vaccination

Please follow the national guidelines concerning vaccination.

HHT and SARS-CoV-2 vaccination

SARS-CoV-2 vaccination is encouraged in patients with HHT, particularly if patients require regular hospital attendance (e.g. for blood transfusions or iron), are older (>50 years old), or have comorbidities such as chronic respiratory disease, cardiovascular diseases, obesity or diabetes.

Vaccination during pregnancy should follow national guidelines for pregnancy.

There are no data to exclude HHT patients from receiving any of the vaccines currently in use.

More information available at: <https://vascern.eu>